<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">3351</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prospects for the use of modern methods of drug treatment of uterine fibroids</article-title><trans-title-group xml:lang="ru"><trans-title>Перспективы использования современных методов лекарственной терапии миомы матки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stykin</surname><given-names>Y O</given-names></name><name xml:lang="ru"><surname>Стыкин</surname><given-names>Ярослав Олегович</given-names></name></name-alternatives><email>stikyar@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Galina</surname><given-names>T V</given-names></name><name xml:lang="ru"><surname>Галина</surname><given-names>Татьяна Вадимировна</given-names></name></name-alternatives><email>tatyana.galina1@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2016</year></pub-date><issue>2</issue><issue-title xml:lang="en">NO2 (2016)</issue-title><issue-title xml:lang="ru">№2 (2016)</issue-title><fpage>202</fpage><lpage>207</lpage><history><date date-type="received" iso-8601-date="2016-09-07"><day>07</day><month>09</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="ru">Copyright ©; 2016, Стыкин Я.О., Галина Т.В.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Стыкин Я.О., Галина Т.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/3351">https://journals.rudn.ru/medicine/article/view/3351</self-uri><abstract xml:lang="en">In the present review of the literature discusses treatment options for uterine fibroids in women of reproductive age based on current possibilities of pathogenetic therapy.</abstract><trans-abstract xml:lang="ru">В представленном обзоре литературы рассматриваются варианты лечения миомы матки у женщин репродуктивного возраста, основанные на современных возможностях патогенетической терапии.</trans-abstract><kwd-group xml:lang="en"><kwd>uterine fibroids</kwd><kwd>antiprogestins</kwd><kwd>SPRM</kwd><kwd>GnRH</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>миома матки</kwd><kwd>аГнРГ</kwd><kwd>СМРП</kwd><kwd>антипрогестины</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Carbonell J.L., Acosta R. et al. Treatment of Uterine Myoma with 2.5 or 5mg Mifepristone Daily during 3 Months with 9 Months. Posttreatment Followup: Randomized Clinical Trial. 2013. No. 2. P. 2-6.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chwalisz K., DeManno D., Garg R. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin. Reprod. Med. 2004. Vol. 22. Iss. 2. P. 113-119.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Croxtall J.D. Ulipristal acetate: in uterine fibroids. Drugs. 2012. Vol. 72. Iss. 8. P. 1075-1085.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cobellis L., Pecori E., Cobellis G. Comparison of intramural myomectomy scar after laparotomy or laparoscopy. Int. J. Gynaecology Obstetrics. 2004. Vol. 84. Iss. 1. P. 87-93.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Donnez J., Tatarchuk T.F., Bouchard P. et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012. Vol. 366. Iss. 5. P. 409-420.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Donnez J., Tomaszewski J., Vazquez F. et al. For the PEARL III Study Group. Long term treatment. Gynecology and Menopause. 2014. P. 9-18.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Donnez J., Tomaszewski J., Vázquez F. et al. Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. N. Engl. J. Med. 2012. Vol. 366. P. 421-432.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Engman M., Granberg S. et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009. No. 8. P. 18-21.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hoellen F., Griesinger G., Bohlmann M.K. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Levens E.D., Potlog-Nahari C. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 2008. Vol. 111. Iss. 5. P. 1129-1136.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lethaby A., Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin. Evid. (Online). 2011.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Maruo T., Ohara N. et al. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas. Expert Opin. Drug Discov. 2011. Vol. 6. Iss. 9. P. 897-911.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Melis G.B., Piras B. et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin. Drug Metab. Toxicol. 2012. Vol. 10. P. 34-38.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Radzinsky V.E., Fuks A.M. Gynecology. Geotar-media, 2014. Р. 1000.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Roeder H., Jayes F. et al. CDB-4124 does not cause apoptosis in cultured fibroid cells. Reprod. Sci. 2011. Vol. 18. Iss. 9. P. 850-857.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Su Y., Lian Q.Q., Ge R.S. Contraceptives with novel benefits. Expert Opin. Investig. Drugs. 2012. Vol. 21. Iss. 1. P. 83-90.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Shtoch E.A., Tschai V.B. Uterine leiomyoma. Modern understanding of the pathogenesis and risk factors. Siberian medical review. 2015. No. 1. Р. 45-48.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Szamatowicz М., Kotarski J. Selective progesterone receptor modulator (ulipristal acetate-a new option in the pharmacological treatment of uterine fibroids in women. Ginekol. Pol. 2013. Vol. 84. Iss. 3. P. 219-222.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tristan M., Orozco L.J. et al. Mifepristone for uterine fibroids. Cochrane Database Syst. Rev. 2012. No. 2.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Tichomirov A.L. New features of pathogenetic treatment of uterine fibroids. Gynecology. 2013. Vol. 6. Iss. 15. P. 36-38.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Radzinsky V.E., Totchiev G.F. Uterine fibroids: a course on organ preservation. News bulletin. Media bureau Status Presens. 2014. P. 24.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yoshida S., Ohara N. et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010. Vol. 28. Iss. 3. P. 260-273.</mixed-citation></ref></ref-list></back></article>
